Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576 - Castro, Januario E.; Lengerke-Diaz, Paula A.; Velez Lujan, Juliana; Choi, Michael Y.; Moreno-Cortes, Eider F.; Forero, Jose V.; Garcia-Robledo, Juan Esteban; Jacobs, Chaja; McCarthy, Colin; Heinen, Alaina; Amaya-Chanaga, Carlos I.; Kipps, Thomas J. (Advances in Hematology, 2022)